These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17388708)

  • 21. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
    Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
    J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
    Kelly DL; Buchanan RW; Boggs DL; McMahon RP; Dickinson D; Nelson M; Gold JM; Ball MP; Feldman S; Liu F; Conley RR
    J Clin Psychiatry; 2009 Apr; 70(4):518-25. PubMed ID: 19358788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
    Dalai SS; Adler S; Najarian T; Safer DL
    Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
    Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
    Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
    Weintraub D; Mavandadi S; Mamikonyan E; Siderowf AD; Duda JE; Hurtig HI; Colcher A; Horn SS; Nazem S; Ten Have TR; Stern MB
    Neurology; 2010 Aug; 75(5):448-55. PubMed ID: 20679638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial.
    Guerdjikova AI; McElroy SL; Welge JA; Nelson E; Keck PE; Hudson JI
    Int Clin Psychopharmacol; 2009 May; 24(3):150-8. PubMed ID: 19357528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
    Safer DL; Adler S; Dalai SS; Bentley JP; Toyama H; Pajarito S; Najarian T
    Int J Eat Disord; 2020 Feb; 53(2):266-277. PubMed ID: 31721257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
    White MA; Grilo CM
    J Clin Psychiatry; 2013 Apr; 74(4):400-6. PubMed ID: 23656848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topiramate in the long-term treatment of binge-eating disorder associated with obesity.
    McElroy SL; Shapira NA; Arnold LM; Keck PE; Rosenthal NR; Wu SC; Capece JA; Fazzio L; Hudson JI
    J Clin Psychiatry; 2004 Nov; 65(11):1463-9. PubMed ID: 15554757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis.
    Sumner CR; Schuh KJ; Sutton VK; Lipetz R; Kelsey DK
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):699-711. PubMed ID: 17201614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.
    Arnold LM; McElroy SL; Hudson JI; Welge JA; Bennett AJ; Keck PE
    J Clin Psychiatry; 2002 Nov; 63(11):1028-33. PubMed ID: 12444817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial.
    Hudson JI; McElroy SL; Raymond NC; Crow S; Keck PE; Carter WP; Mitchell JE; Strakowski SM; Pope HG; Coleman BS; Jonas JM
    Am J Psychiatry; 1998 Dec; 155(12):1756-62. PubMed ID: 9842788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
    Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.